Novo Nordisk increased operating profit in local currencies by 12% in the first six months of 2014
7 August 2014 | By Novo Nordisk
7% sales growth in local currencies driven by Levemir® and Victoza®...
List view / Grid view
News
Daiichi Sankyo and Charleston Laboratories announce collaboration
7 August 2014 | By Daiichi Sankyo
... to develop and commercialize novel, fixed-dose combination hydrocodone products for pain and opioid-induced nausea and vomiting in the US.
Stem cells: from bench to drug development
Working in stem cell research can be both immensely rewarding and notoriously challenging. One of the most prominent challenges is taking what are often exciting new advances in stem cell biology made in the research lab, and translating these into viable, impactful therapies for patients.
Is the Ebola virus a real threat for Europe and the US?
6 August 2014 | By Frost & Sullivan
“The Zaire Ebola virus causes a highly contagious and lethal hemorrhagic fever leading to the death of the infected individuals..."
EU approves Roche’s Avastin for platinum-resistant recurrent ovarian cancer
6 August 2014 | By Roche
First new treatment option for women in Europe in more than 15 years for most difficult to treat form of ovarian cancer...
Merck publishes 2013 global corporate responsibility report
6 August 2014 | By Merck
Merck issued its 2013 global corporate responsibility report...
Roche to acquire Santaris Pharma to expand discovery and development of RNA-targeting medicines
5 August 2014 | By Roche
Roche announced that it has agreed to acquire Santaris Pharma, a privately held biopharmaceutical company based near Copenhagen, Denmark...
Merck completes tender offer to acquire Idenix
5 August 2014 | By Merck
Merck announced the successful completion of the tender offer for all of the outstanding shares of common stock of Idenix Pharmaceuticals, Inc. at a purchase price of $24.50 per share...
Boehringer Ingelheim receives two FDA approvals
4 August 2014 | By Boehringer Ingelheim
Boehringer Ingelheim today announced the U.S. Food and Drug Administration (FDA) approved two different products at the end of last week.
Amgen announces Phase 3 ASPIRE trial of Kyprolis® in patients with relapsed multiple myeloma met primary endpoint
4 August 2014 | By Amgen
Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE met its primary endpoint of progression-free survival...
European Medicines Agency looks to stimulate better use of genomic data and biomarkers in medicines development and safety monitoring
4 August 2014 | By The European Medicines Agency
The European Medicines Agency has released a draft concept paper for public consultation outlining the key elements that will be developed in a guideline on good genomics biomarker practices...
Allied Minds and Bristol-Myers Squibb form new enterprise to advance discoveries of biopharmaceutical innovations at leading U.S. academic research
4 August 2014 | By Bristol-Myers Squibb Company
Allied Minds and Bristol-Myers Squibb Company announced the formation of Allied-Bristol Life Sciences LLC, a new jointly owned enterprise created to identify and foster research and pre-clinical development of biopharmaceutical innovations...
AbbVie receives EMA and FDA orphan drug designation for investigational compound ABT-414 in the treatment of Glioblastoma multiforme
4 August 2014 | By AbbVie
AbbVie announced the European Medicines Agency and the U.S. Food and Drug Administration have granted orphan drug designation to AbbVie's investigational compound ABT-414...
Alcon’s Simbrinza® approved in the EU to treat patients living with glaucoma, a chronic sight-threatening eye disease
4 August 2014 | By Novartis
Alcon announced that Simbrinza® eye drops suspension (brinzolamide 10mg/mL and brimonidine tartrate 2mg/mL) has been approved by the European Commission to decrease elevated intraocular pressure...
European Medicines Agency invites comments on new overarching guidance for the development of influenza vaccines
31 July 2014 | By The European Medicines Agency
The European Medicines Agency has released the second module of a new overarching guideline on influenza vaccines for a six-month public consultation...
